The founder was a co-author on a publication in Journal of Alzheimer’s disease entitled “Validation of assays for measurement of Amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer’s disease treated with Solanezumab.”
Biomarkable
From Concept to Value – Hugo Vanderstichele
